Plby Group Inc vs uniQure N.V. Ordinary Shares — how do they compare? Plby Group Inc trades at $0.97 (market cap $122.20M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 12.1× Plby Group Inc's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| PLBY | QURE | |
|---|---|---|
Market Cap | $122.20M | $1.48B |
Volume | 540,321 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $70.59 |
52-Week Low | $0.98 | $9.03 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $267.79M | $728.62M |
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $0.99, down 0.32% with a bearish technical signal. The company shows improving fundamentals with revenue stabilizing around $121M in 2025 and narrowing losses from -$278M in 2022 to -$13M. Recent Q2 2026 earnings beat expectations with positive operating cash flow. Analyst sentiment remains strong with 75% buy ratings, while technical indicators show oversold conditions with RSI at neutral levels.
The outlook suggests cautious optimism as PLBY demonstrates operational improvement and debt reduction, though negative shareholder equity and high P/E ratio of 51 present valuation concerns. Key risks include persistent negative equity and competitive pressures in the consumer discretionary space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →